Our Programs

Our pipeline includes four clinical-stage drug candidates targeting different mechanisms critical to overcoming cancer progression and drug resistance:

  • Pracinostat, an oral HDAC inhibitor;
  • ME-401, an oral PI3K delta inhibitor;
  • Voruciclib, an oral CDK inhibitor; and
  • ME-344, a mitochondrial inhibitor targeting the OXPHOS complex.

Our portfolio is built around drug candidates with validated targets and is designed to develop medicines that are: (1) differentiated, (2) address unmet medical needs and (3) deliver improved benefit to patients either as standalone treatments or in combination with other medicines.

HDAC Inhibitor

DRUG CANDIDATE

Pracinostat HDAC Inhibitor

INDICATION / COMBINATION

Acute Myeloid Leukemia

Unfit for intensive chemotherapy
Vidaza® (azacitidine)
Pre-Clinical
Clinical Proof-Of-Concept
Pivotal
INDICATION / COMBINATION

Myelodysplastic Syndrome

High & very high risk
Vidaza® (azacitidine)
Pre-Clinical
Clinical Proof-Of-Concept
Pivotal

PI3K Delta Inhibitor

DRUG CANDIDATE

ME-401 PI3K Delta Inhibitor

INDICATION / COMBINATION

Follicular Lymphoma

Relapsed/refractory
Single agent
Pre-Clinical
Clinical Proof-Of-Concept
Pivotal
INDICATION / COMBINATION

B-Cell Malignancies

Relapsed/refractory
Single-agent
• Rituxan® (rituximab)
• Zanubrutinib
Pre-Clinical
Clinical Proof-Of-Concept
Pivotal

Selective CDK Inhibitor

DRUG CANDIDATE

Voruciclib CDK Inhibitor

INDICATION / COMBINATION

B-Cell Malignancies

Relapsed/refractory
Single agent
Pre-Clinical
Clinical Proof-Of-Concept
Pivotal

Mitochondrial Inhibitor

DRUG CANDIDATE

ME-344 Mitochondrial Inhibitor

INDICATION / COMBINATION

HER2-Breast Cancer§

Treatment-naïve, early stage
Avastin® (bevacizumab)
Pre-Clinical
Clinical Proof-Of-Concept
Pivotal

 

† Phase 2 study intended to support an accelerated approval marketing application with the FDA
‡ Study arm to be initiated under clinical collaboration with Beigene, Ltd.
§ Investigator-initiated study